Cantor Fitzgerald Reiterates Overweight on IRulya Therapeutics, Maintains $70 Price Target
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates IRulya Therapeutics (NASDAQ:IRLA) with a Overweight and maintains $70 price target.
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates IRulya Therapeutics (NASDAQ:IRLA) with a Overweight and maintains $70 price target.
